Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Esanex Inc.
ClinicalTrials.gov Identifier:
NCT01851096
First received: May 4, 2013
Last updated: August 15, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2016
  Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)